Eric A. Adams
Known title: President & CEOCIK: 0001817882
Eric A. Adams's purchase track record
How the stock did after each of Eric A. Adams's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since September 28, 2021
Stock higher 6 months later
33%
3 months: 0%
Median 6-month return
-42.9%
3 months: -25.8%
Beat the S&P 500
33%
median -49.3% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/20/2024 | INM | $15K | -12.5% | +14.6% | +12.5% |
| 4/13/2022 | INM | $20K | -50.5% | -72.5% | -19.6% |
| 9/28/2021 | INM | $35K | -25.8% | -42.9% | +6.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| INM | ▲ Buy | Open Market | 41,600 | $15K | 2/20/2024 | View on chart |
| INM | ▲ Buy | Open Market | 14,160 | $13K | 4/14/2022 | View on chart |
| INM | ▲ Buy | Open Market | 8,560 | $7K | 4/13/2022 | View on chart |
| INM | ▲ Buy | Open Market | 8,800 | $15K | 9/29/2021 | View on chart |
| INM | ▲ Buy | Open Market | 11,400 | $20K | 9/28/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
INM: No recent news reported
There were no new announcements or events involving InMed Pharmaceuticals in the past week. The only article listed concerns Liquidia, which does not affect INM directly. Therefore, no new information is available to influence the company's outlook at this time.
INM: No recent news reported. There were no new announcements or events involving InMed Pharmaceuticals in the past week. The only article listed concerns Liquidia, which does not affect INM directly. Therefore, no new information is available to influence the company's outlook at this time.